新设备可通过血液快速确诊阿尔茨海默病

2019-06-27 蔡蜀亚 新华网

新加坡国立大学一个科研团队在新一期英国《自然·通讯》杂志上报告,他们研发出一套检测系统,通过检测血液样本即可快速确诊阿尔茨海默病。

新加坡国立大学一个科研团队在新一期英国《自然·通讯》杂志上报告,他们研发出一套检测系统,通过检测血液样本即可快速确诊阿尔茨海默病。

阿尔茨海默病通常到晚期才被发现,早期发现和干预对提升该病治疗效果有重要意义。新加坡国立大学下属医疗健康创新与科技研究院副教授邵惠琳领衔的团队发明的这个名为Apex的系统,临床试验证明可以早在患者还没出现明显临床症状时就发现病情。

目前,诊断阿尔茨海默病最准确可靠的方法是让患者接受脑部数字正电子发射断层成像(PET)扫描,需要依赖复杂的检测设备。而Apex测试费用只需30美元,仅为扫描价格的1%,且操作简单,结果可在一小时内出炉。这一新检测系统将对现有阿尔茨海默病诊断管理体系提供强大和有效的辅助作用。

阿尔茨海默病的一个重要特征是患者大脑中贝塔淀粉样蛋白出现异常蓄积导致脑细胞受损。这种蛋白质会被释放到血液中进入循环系统。Apex检测系统利用传感器上的数以百万计的纳米孔捕捉血液中可能存在的这种蛋白质,一旦捕捉到就会发出红色信号。感应器捕捉到的这种蛋白质越多,红色信号就越强,代表病情越为严重。

该团队招募了84名志愿者进行临床试验,其中包括已确诊的阿尔茨海默病患者、轻度认知障碍患者、其他类型神经退行性疾病患者以及身体健康者等。PET扫描和Apex系统血液测试对比结果显示,Apex能准确识别阿尔茨海默病和认知障碍患者,并能将他们与健康人及其他神经退行性疾病患者区分开来,准确程度与PET扫描相当。(记者蔡蜀亚)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1817944, encodeId=0114181e9445b, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 02 08:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816921, encodeId=805318169213d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri May 22 10:43:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041208, encodeId=c005204120882, content=<a href='/topic/show?id=4697586e85a' target=_blank style='color:#2F92EE;'>#新设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58678, encryptionId=4697586e85a, topicName=新设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 17:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470298, encodeId=b4a514e029883, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 12:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368515, encodeId=0822368515d4, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jun 28 07:39:21 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1817944, encodeId=0114181e9445b, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 02 08:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816921, encodeId=805318169213d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri May 22 10:43:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041208, encodeId=c005204120882, content=<a href='/topic/show?id=4697586e85a' target=_blank style='color:#2F92EE;'>#新设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58678, encryptionId=4697586e85a, topicName=新设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 17:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470298, encodeId=b4a514e029883, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 12:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368515, encodeId=0822368515d4, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jun 28 07:39:21 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1817944, encodeId=0114181e9445b, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 02 08:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816921, encodeId=805318169213d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri May 22 10:43:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041208, encodeId=c005204120882, content=<a href='/topic/show?id=4697586e85a' target=_blank style='color:#2F92EE;'>#新设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58678, encryptionId=4697586e85a, topicName=新设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 17:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470298, encodeId=b4a514e029883, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 12:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368515, encodeId=0822368515d4, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jun 28 07:39:21 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1817944, encodeId=0114181e9445b, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 02 08:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816921, encodeId=805318169213d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri May 22 10:43:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041208, encodeId=c005204120882, content=<a href='/topic/show?id=4697586e85a' target=_blank style='color:#2F92EE;'>#新设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58678, encryptionId=4697586e85a, topicName=新设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 17:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470298, encodeId=b4a514e029883, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 12:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368515, encodeId=0822368515d4, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jun 28 07:39:21 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1817944, encodeId=0114181e9445b, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Jul 02 08:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816921, encodeId=805318169213d, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Fri May 22 10:43:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041208, encodeId=c005204120882, content=<a href='/topic/show?id=4697586e85a' target=_blank style='color:#2F92EE;'>#新设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58678, encryptionId=4697586e85a, topicName=新设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 17:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470298, encodeId=b4a514e029883, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 12:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368515, encodeId=0822368515d4, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Fri Jun 28 07:39:21 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-06-28 百草

    666

    0

相关资讯

第14届阿尔茨海默症和帕金森国际会议:Aptinyx将介绍NYX-458的临床前数据

Aptinyx是一家临床阶段的生物制药公司,开发用于治疗大脑和神经系统疾病的变革疗法,近日宣布即将在第14届阿尔茨海默症和帕金森国际会议上发表演讲,重点介绍其新型NMDA受体调节剂NYX-458的临床前数据

Masitinib治疗阿尔茨海默症的AB09004研究的中期分析结果

AB09004研究是一项国际性、随机、安慰剂对照的III期研究,正在评估Masitinib治疗轻度至中度阿尔茨海默症。该研究评估了Masitinib联合胆碱酯酶抑制剂和/或美金刚的有效性和安全性。

2018年 阿尔茨海默病领域的10大重磅交易

全球大约有几千万名的阿尔茨海默病患者。阿尔茨海默病患者的两大重要病理特征为大脑中的淀粉样蛋白(Aβ)沉积和神经细胞中tau蛋白聚集导致的神经原纤维缠结。

第14届阿尔茨海默症和帕金森国际会议:Eisai将公布其一系列在研药物的临床试验结果

Eisai公司近日宣布,将于3月26日举行的第14届阿尔茨海默症和帕金森国际会议上公布其一系列在研药物的临床试验结果:BAN2401,一种抗淀粉样蛋白β(Aβ)初原纤维抗体,正在进行III期试验;elenbecestat,一种口服选择性BACE1抑制剂,目前正在进行两项III期研究(MISSION AD1 / 2)。

“绕开”致病蛋白!预防老年痴呆症的基因疗法试验即将启动

将来有一天,APOE4患者去看医生,一次性注射APOE2,或许就能预防阿尔茨海默症。

由于毒理学发现,Allergan/Sosei公司将延迟阿尔茨海默症新药HTL0018318的临床开发

由于在非人类灵长类动物的研究中意外发现的毒理作用,Allergan和Sosei自愿暂停HTL0018318的临床开发工作。